Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel

Susan Halabi; Sandipan Dutta; Catherine M Tangen; Mark Rosenthal; Daniel P Petrylak; Ian M Thompson Jr; Kim N Chi; Johann S De Bono; John C Araujo; Christopher Logothetis; Mario A Eisenberger; David I Quinn; Karim Fizazi; Michael J Morris; Celestia S Higano; Ian F Tannock; Eric J Small; William Kevin Kelly

doi:10.1093/jncics/pkaa003

Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel

JNCI Cancer Spectr. 2020 Jan 29;4(2):pkaa003. doi: 10.1093/jncics/pkaa003. eCollection 2020 Apr.

Authors

Susan Halabi¹, Sandipan Dutta², Catherine M Tangen³, Mark Rosenthal⁴, Daniel P Petrylak⁵, Ian M Thompson Jr⁶, Kim N Chi⁷, Johann S De Bono⁸, John C Araujo⁹, Christopher Logothetis⁹, Mario A Eisenberger¹⁰, David I Quinn¹¹, Karim Fizazi¹², Michael J Morris¹³, Celestia S Higano¹⁴, Ian F Tannock¹⁵, Eric J Small¹⁶, William Kevin Kelly¹⁷

Affiliations

¹ Department of Biostatistics and Bioinformatics, School of Medicine, Duke University, Durham, NC, USA.
² Department of Mathematics and Statistics, Old Dominion University, Norfolk, VA, USA.
³ Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
⁴ Department of Medical Oncology, Peter MacCallum Cancer Centre, Parkville, Australia.
⁵ Medical Oncology, Yale School of Medicine, New Haven, CT, USA.
⁶ President, Christus San Rosa Hospital Medical Center, San Antonio, TX, USA.
⁷ Medical Oncology, British Columbia Cancer Agency - Vancouver Centre, Vancouver, BC, USA.
⁸ Division of Clinical Studies, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK.
⁹ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹⁰ Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
¹¹ Genitourinary Oncology, Department of Medicine University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
¹² Medical Oncology, Gustave Roussy, Villejuif, France.
¹³ Genitourinary Oncology Service, Department of Medicine. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁴ Department of Medicine, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
¹⁵ Department of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
¹⁶ Department of Medicine, and University of California San Francisco Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
¹⁷ Medical Oncology and Urology, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA, USA.

Abstract

There are few data regarding disparities in overall survival (OS) between Asian and white men with metastatic castration-resistant prostate cancer (mCRPC). We compared OS of Asian and white mCRPC men treated in phase III clinical trials with docetaxel and prednisone (DP) or a DP-containing regimen. Individual participant data from 8820 men with mCRPC randomly assigned on nine phase III trials to receive DP or a DP-containing regimen were combined. Men enrolled in these trials had a diagnosis of prostate adenocarcinoma. The median overall survival was 18.8 months (95% confidence interval [CI] = 17.4 to 22.1 months) and 21.2 months (95% CI = 20.8 to 21.7 months) for Asian and white men, respectively. The pooled hazard ratio for death for Asian men compared with white men, adjusted for baseline prognostic factors, was 0.95 (95% CI = 0.84 to 1.09), indicating that Asian men were not at increased risk of death. This large analysis showed that Asian men did not have shorter OS duration than white men treated with docetaxel.

Abstract

Grants and funding